Bone-modifying agents and survival in patients treated with immune checkpoint inhibitors

Onur Baş; Nesime İnci Güner; Mert Tokatlı; Naciye Güdük; Taha Koray Şahin; Nadir Yalçın; Sercan Aksoy

Makale detayları

Bone-modifying agents and survival in patients treated with immune checkpoint inhibitors

Yazarlar:

Onur Baş | Nesime İnci Güner | Mert Tokatlı | Naciye Güdük | Taha Koray Şahin | Nadir Yalçın | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları | Klinik Onkoloji

Dergi:

Journal of Medicine and Palliative Care Vol.6 Issue 4, pp.328-331

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357446

pISSN:

2717-7505

Anahtar kelimeler:

Özet:

 Aims: Management of bone metastasis is crucial for cancer patients. The objective of this study was to assess the correlation between survival outcomes and bone-modifying agents BMAs in patients treated with immune checkpoint inhibitors ICIs. Methods: This study was conducted in individuals who received at least 3 doses of ICIs between January 2018 and December 2023 and had bone metastases at initiation of ICIs. We retrospectively collected data on each patient from their medical records, including information on cancer, the specific immunotherapy treatment, and the BMAs they were receiving. Results: 142 patients were included. The median follow-up was 36 interquartile range IQR18-50 months and the median follow-up from the initiation of BMAs to the last control was 14 months IQR5-29. After adjustment for age, gender, Eastern Cooperative Oncology Group ECOG score and number of prior treatment lines in the multivariate analyses, patients who did not use BMAs had decreased overall survival OS HR: 2.30, 95CI: 1.03-2.45; p0.036. In addition, BMAs use was associated with long-term benefit defined as having a survival of equal to or longer than 24 months HR: 2.85, 95CI 1.13-7.21; p0.027. Conclusion: It was found that using BMAs could be an independent predictor of OS in patients treated with ICI and who had bone metastasis. This finding may lead clinicians to start BMAs as soon as possible after bone metastases are detected.

 Aims: Management of bone metastasis is crucial for cancer patients. The objective of this study was to assess the correlation between survival outcomes and bone-modifying agents BMAs in patients treated with immune checkpoint inhibitors ICIs. Methods: This study was conducted in individuals who received at least 3 doses of ICIs between January 2018 and December 2023 and had bone metastases at initiation of ICIs. We retrospectively collected data on each patient from their medical records, including information on cancer, the specific immunotherapy treatment, and the BMAs they were receiving. Results: 142 patients were included. The median follow-up was 36 interquartile range IQR18-50 months and the median follow-up from the initiation of BMAs to the last control was 14 months IQR5-29. After adjustment for age, gender, Eastern Cooperative Oncology Group ECOG score and number of prior treatment lines in the multivariate analyses, patients who did not use BMAs had decreased overall survival OS HR: 2.30, 95CI: 1.03-2.45; p0.036. In addition, BMAs use was associated with long-term benefit defined as having a survival of equal to or longer than 24 months HR: 2.85, 95CI 1.13-7.21; p0.027. Conclusion: It was found that using BMAs could be an independent predictor of OS in patients treated with ICI and who had bone metastasis. This finding may lead clinicians to start BMAs as soon as possible after bone metastases are detected.

 Aims: Management of bone metastasis is crucial for cancer patients. The objective of this study was to assess the correlation between survival outcomes and bone-modifying agents BMAs in patients treated with immune checkpoint inhibitors ICIs. Methods: This study was conducted in individuals who received at least 3 doses of ICIs between January 2018 and December 2023 and had bone metastases at initiation of ICIs. We retrospectively collected data on each patient from their medical records, including information on cancer, the specific immunotherapy treatment, and the BMAs they were receiving. Results: 142 patients were included. The median follow-up was 36 interquartile range IQR18-50 months and the median follow-up from the initiation of BMAs to the last control was 14 months IQR5-29. After adjustment for age, gender, Eastern Cooperative Oncology Group ECOG score and number of prior treatment lines in the multivariate analyses, patients who did not use BMAs had decreased overall survival OS HR: 2.30, 95CI: 1.03-2.45; p0.036. In addition, BMAs use was associated with long-term benefit defined as having a survival of equal to or longer than 24 months HR: 2.85, 95CI 1.13-7.21; p0.027. Conclusion: It was found that using BMAs could be an independent predictor of OS in patients treated with ICI and who had bone metastasis. This finding may lead clinicians to start BMAs as soon as possible after bone metastases are detected.

 Giriş: Kemik metastazlarının yönetimi kanser hastaları için çok önemlidir. Bu çalışmanın amacı, immün kontrol noktası inhibitörleri ICI ile tedavi edilen hastalarda sağkalım sonuçları ile kemik koruyucu ajan BMA kullanımı arasındaki ilişkiyi değerlendirmektir. Method: Bu çalışmaya, Ocak 2018 ile Aralık 2023 arasında en az 3 doz ICI alan ve ICI tedavisine başlanıldığı esnada kemik metastazı olan hastalar dahil edilmiştir. Hastalar ait olan kanser tipi, spesifik immünoterapi tedavisi ve aldıkları BMAlarla ilgili bilgiler de dahil olmak üzere bütün veriler retrospektif olarak hastane kayıt sisteminden elde edilmiştir. Bulgular: 142 hasta çalışmaya dahil edilmiştir. Ortanca takip süresi 36 Çeyrekler arası aralık IQR18-50 ay ve BMAların başlanmasından son kontrole kadar olan ortanca takip süresi 14 aydı IQR5-29. Çok değişkenli analizlerde yaş, cinsiyet, Eastern Cooperative Oncology Group Scale ECOG skoru ve önceki tedavi sayısı için ayarlama yapıldığında, BMA kullanmayan hastalarda genel sağkalım süresinin daha kısa olduğu görülmüştür. HR: 2.30, 95CI: 1.03-2.45; p0.036. Ayrıca, BMA kullanımının 24 aya eşit veya daha uzun sağkalım olarak tanımlanan uzun dönem fayda ile ilişkili olduğu görülmüştür. HR: 2.85, 95CI 1.13-7.21; p0.027. Sonuç: Kemik koruyucu ajanların kullanılmasının, ICI ile tedavi edilen ve kemik metastazı olan hastalarda genel sağkalımın bağımsız bir belirleyicisi olabileceği bulunmuştur. Bu bulgu, klinisyenleri kemik metastazları tespit edildikten sonra mümkün olan en kısa sürede BMAlara başlamaya yönlendirebilir.

Makale detayları

Bone-modifying agents and survival in patients treated with immune checkpoint inhibitors

Yazarlar:

Onur Baş | Nesime İnci Güner | Mert Tokatlı | Naciye Güdük | Taha Koray Şahin | Nadir Yalçın | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları | Klinik Onkoloji

Dergi:

Journal of Medicine and Palliative Care Vol.6 Issue 4, pp.328-331

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357446

pISSN:

2717-7505

Immune checkpoint inhibitors

denosumab

zoledronic acid

survival

long-term benefitİmmün kontrol noktası inhibitörleri

denosumab

zoledronik asit

sağkalım

uzun dönem fayda

Sayı

Makale detayları

Yazarlar: Onur Baş | Nesime İnci Güner | Mert Tokatlı | Naciye Güdük | Taha Koray Şahin | Nadir Yalçın | Sercan Aksoy

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: İç Hastalıkları | Klinik Onkoloji

Dergi: Journal of Medicine and Palliative Care Vol.6 Issue 4, pp.328-331

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001357446

pISSN: 2717-7505

Sayı

Yazarlar:

Onur Baş | Nesime İnci Güner | Mert Tokatlı | Naciye Güdük | Taha Koray Şahin | Nadir Yalçın | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

İç Hastalıkları | Klinik Onkoloji

Dergi:

Journal of Medicine and Palliative Care Vol.6 Issue 4, pp.328-331

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001357446

pISSN:

2717-7505